First Reported Cases of COVID-19-Associated Mucormycosis in Tunisia

Rim Khemakhem 1 *, Ichrak Bougharriou 2 *, Nesrine Kallel 1 *, Anis Bafoun 2 *, Feten Mahmoudi 2 *, Samy Kammoun 1 *

INTRODUCTION

Mucormycosis is uncommon and mostly occurs in patients with immunodeficiency. COVID-19-associated mucormycosis (CAM) was reported in many countries. It is caused primarily by immunosuppression due to COVID-19, corticosteroid therapy and high blood sugar [1]. We report here, to our knowledge, the first published cases of CAM in Tunisia.

CASES REPORTS

Case 1

The first case was a diabetic, 68-year-old man. He had dyspnea and fever, evolving for four days. The SARS-CoV-2 infection was confirmed by nasopharyngeal swab. A computed tomography (CT) scan of the chest showed multiple ground-glass opacities in 80% of both lungs with peripheral distribution. We prescribed dexamethasone (4 mg twice daily), general supportive care and subcutaneous enoxaparin (0.4 ml twice daily). One week after, he gradually deteriorated with the onset of acute respiratory distress syndrome. A right eyelid edema with ptosis and periorbital and nasal necrosis were noted (Figure 1).

C-reactive protein (CRP) was 105 mg/l. CT scan of the orbits and sinuses showed a soft tissue swelling in the right preseptal regions and mild right proptosis (Figure 2).

The mycological study of the nasal swab confirmed the diagnosis of mucormycosis. The patient received amphotericin B deoxycholate (1 mg/kg/day). But he continued to deteriorate with neurological symptoms and blindness and surgical treatment was not possible. The patient died a week later.

Case 2

The second case was a 37-year-old woman with a chronic renal failure hemodialysis stage and liver disease. She presented with cough and dyspnea. COVID-19 infection was confirmed by throat swab. She received dexamethasone (4 mg twice daily), subcutaneous enoxaparin (0.4 ml once daily), and oxygen (3 l/min). On the 7th day of hospitalization, the patient presented with edema of the left hemiface, ptosis, nasal, perinasal, and perioral necrosis and fever (Figure 3).

A CT scan of the orbits and sinuses showed severe pansinusitis, mucosal opacification of the ostiomeatal units and several abscess. Mucormycosis was confirmed by the mycological study of a nasal swab. Surgical treatment was not possible due to the extension of lesions. Amphotericin B deoxycholate (0.5 mg/kg/48hours) was administered. The patient continued to experience worsening and died few weeks later.

DISCUSSION

Mucormycosis is caused by environmental fungi belonging to the class zygomycetes, order mucorales. Contamination is through the inhalation of fungal spores [1]. It has a vascular tropism, inducing thrombosis and host tissue necrosis [2, 3]. It is a rare and fatal opportunistic fungal infection. Risk factors...
include diabetes (especially uncontrolled or with ketoacidosis), cancer, organ or stem cell transplantation, immunosuppressive or deferoxamine or corticosteroid use, immunocompromised individuals, hemochromatosis, neutropenia, severe burn, and post traumatic open wound [3,4].

The COVID-19 infection is a new predisposing factor. CAM was described in 100 patients, in a recent systematic review. The majority of patients are from India (68.68%) [4]. No COVID-19 related case is previously published from Tunisia. Mucormycosis essentially occurs in severe or critical COVID-19 infection, but also in mild or moderate one [5]. It occurs during COVID-19 infection (53%) or in post-COVID-19 disease (47%) [4]. Mucormycosis occurs on average 15 days after COVID-19 infection [5]. CAM is mainly due to corticosteroid use, high blood sugar, prolonged antibiotic therapy, and mechanical ventilation.

Several other factors are reported: elevated serum ferritin and iron, endothelitis, humid climate, tissue hypoxia, dissemination of spores through water humidifying oxygen, viral-induced lymphopenia, phagocyte dysfunction, and high inflammatory cytokines levels such as interleukin-6 [4-7]. In a recent review [4], different clinical forms of CAM are reported. The most frequent one are rhino-orbital (50%), rhino-sinusal (17%), and rhino-orbito-cerebral (15%).

The main clinical manifestations of these forms are: fever, nasal secretions, nasal or palatine eschar, unilateral facial edema, orbital symptoms (exophtalmos, ptosis, diplopia, and blindness), and neurological symptoms (headache, localising signs, and seizures) [2,8]. MRI or CT scan evaluate the sinus, orbital, endocranial, and vascular extension [8]. The diagnosis of mucormycosis is confirmed by mycological study or anatomopathological examination of the local sample [8, 9]. Rhino-orbito-cerebral mucormycosis is classified as possible (only clinical signs), probable (clinical signs with diagnostic nasal endoscopy findings or MRI or CT scan), and proven (clinical and radiological signs with mycological confirmation) [8].

Mucormycosis’s treatment is based on antifungal therapy, surgical debridement of necrotic tissues, glycemic control, and reversal of immunosuppression if it’s possible [8,10]. The first-line indicated antifungal treatment is liposomal amphotericin B. If not available, we can use amphotericin B deoxycholate or amphotericin B lipid complex [8,10]. Posaconazole and isavuconazole can also be used [2]. It was shown that despite adequate medical and surgical treatment, mortality remains high (34%) [5].

Herein, we presented two cases of proven mucormycosis associated with severe COVID-19 infection. Clinical forms were rhino-orbito-cerebral and rhino-sinus-orbital. The first patient was old and diabetic and the second presented a chronic renal failure hemodialysis stage and liver disease. The signs of CAM were noted after one week of admission for COVID-19 infection and treatment with steroids. The two patients received amphotericin B deoxycholate (liposomal amphotericin B, posaconazole, and isavuconazole were not available in Tunisia). Surgical treatment was not possible in the two cases and outcomes were not favorable.

CONCLUSIONS

We must think about mucormycosis as a complication of COVID-19 infection. Diagnosis and treatment must be urgents to improve the prognosis. We may be able to reduce the incidence of CAM by optimizing the use of corticosteroids.
Author contributions: All authors have sufficiently contributed to the study, and agreed with the results and conclusions.
Funding: No funding source is reported for this study.
Declaration of interest: No conflict of interest is declared by authors.

REFERENCES

1. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146. doi:10.1016/j.dsx.2021.05.019 PMid:34192610 PMCid:PMC8137376

2. Mohammadi F, Badri M, Safari S, Hemmat N. A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: A systematic review of literature and current update. BMC Infect Dis. 2021;21(1):906. doi:10.1186/s12879-021-06625-3 PMid:34479495 PMCid:PMC8415695

3. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264.e5-264.e8. doi:10.1016/j.ajem.2020.09.032 PMid:32972795 PMCid:PMC7493738

4. Dilek A, Ozaras R, Ozkaya S, Sunbul M, Sen EI, Leblebicioglu H. COVID-19-associated mucormycosis: Case report and systematic review. Travel Med Infect Dis. 2021;44:102148. doi:10.1016/j.tmaid.2021.102148 PMid:34454090 PMCid:PMC8387131

5. Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses. 2021;64(12):1452-9. doi:10.1111/myc.13338 PMid:34133798 PMCid:PMC8447126

6. do Monte Junior ES, Dos Santos MEL, Ribeiro IB, et al. Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: A case report. Clin Endosc. 2020;53(6):746-9. doi: 10.5946/ce.2020.180 PMid:33207116 PMCid:PMC7719411

7. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):e10726. doi:10.7759/cureus.10726 PMid:33145132 PMCid:PMC7599039

8. Honavar SG. Code mucor: Guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol. 2021;69(6):1361-5. doi:10.4103/ijo.IJO_1165_21 PMid:34011699 PMCid:PMC8302268

9. Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi (Basel). 2020;6(4):265. doi:10.3390/jof6040265 PMid:33147877 PMCid:PMC7711598

10. Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthalmic Plast Reconstr Surg. 2021;37(2):e40-80. doi:10.1097/IOP.0000000000001889 PMid:33229953 PMCid:PMC7927902